SAN DIEGO, Feb. 7, 2018 /PRNewswire/ -- Abide Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting the serine hydrolase family of enzymes, announced today that Alan Ezekowitz, CEO and President, will present an overview of the company at the 20th Annual BIO CEO & Investor Conference on Monday, February 12th at 11:30 a.m. ET in New York City. Abide will also participate in the Leerink Partners 7th Annual Global Healthcare Conference in New York City, and will be available for meetings on Wednesday, February 14th.
"Over the past year, Abide has made tremendous progress utilizing our innovative discovery platform to create a deep first-in-class pipeline targeting serine hydrolases," said Dr. Ezekowitz. "Last year we released positive topline data from our Phase 1b study of our lead candidate, ABX-1431, which demonstrated statistically significant activity on Tourette symptoms. We look forward to sharing our plans for ABX-1431 in Tourette Syndrome and other CNS diseases, as well as an update on our preclinical pipeline."
About Abide Therapeutics
Abide Therapeutics is focused on developing first-in-class drugs for serious diseases with significant unmet medical need. An innovative discovery platform and a library of proprietary small molecules allow Abide to address biological pathways with therapeutics that enhance the body's normal physiological response to disease. The platform enables Abide to efficiently identify, modify, and validate small-molecule inhibitors that target serine hydrolases, a highly relevant but under-explored class of enzymes. Abide's initial area of focus is on addressing neurological disorders with limited treatment options through the endocannabinoid pathway.
Abide has offices in San Diego, California and Princeton, New Jersey. To learn more, visit www.abidetx.com.
Media Contact:
Patty Pilon
Abide Therapeutics
Tel: +1 619.244.2679
patty@abidetx.com
Investor Contact:
John Graziano
The Trout Group
Tel: +1 646.378.2942
jgraziano@troutgroup.com
SOURCE Abide Therapeutics